This book covers all ethical aspects of introducing novel implants and procedures in neurosurgery in a structured way, addressing the current knowledge gap concerning ethical innovations in neurosurgery. Initially it explores the difficulties involved in defining when a procedure should be considered innovation, research, or care. To this end, it presents not only an overview of current literature, but also data from a recent survey among neurosurgeons in Europe. The book subsequently discusses the ethical issues related to innovation. These include: informed consent (what should a surgeon tell the patient and how should he/she do so), oversight (can any surgeon simply implant a novel spinal device?), the learning curve (when should a surgeon be allowed to perform a novel procedure?), vulnerable patients (how to innovate in the pediatric population or in an emergency setting), and conflicts of interest, as well as the ethics of paying for innovative treatments. In turn, the closing chapters focus on the evaluation of neurosurgical research and innovation. Are cultural changes necessary and how could innovation benefit from (international) collaborations? Given the range of topics addressed, the book offers neurosurgeons, residents, scientists, companies and hospital administrations a valuable guide to introducing novel implants and techniques in neurosurgery.

A comprehensive introduction and practical framework to bioethics, for all who are involved in the management of neurosurgical patients.

Neurosurgical interventions have the potential to change a person's concept of self, as well as affect their neurological and cognitive function to an unacceptable level for both patient and family. In an increasingly complex and evolving field, the ethical implications of treatments and their eventual outcomes must be carefully balanced. Ethics in Neurosurgical Practice is a comprehensive and practical guide for managing the treatment of patients with debilitating neurosurgical conditions. Chapters address specific conditions, such as traumatic brain injuries, ischemic stroke and spinal surgery, and the ethical challenges that each of these pose. Detailed case studies present potential scenarios that readers might encounter, and their outcomes. Future developments of this fast-paced field are expanded upon, including televised live surgery and the ethical aspects of innovation in neurosurgery. A broad variety of contributors in different fields, including neurosurgeons, intensivists and bioethicists, ensures comprehensive coverage from a range of views and experiences.

Improving and Accelerating Therapeutic Development for Nervous System Disorders is the summary of a workshop convened by the IOM Forum on Neuroscience and Nervous System Disorders to examine opportunities to accelerate early phases of drug development for nervous system drug discovery. Workshop participants discussed challenges in neuroscience research for enabling faster entry of potential treatments into first-in-human trials, explored how new and emerging tools and technologies may improve the efficiency of research, and considered mechanisms to facilitate a more effective and efficient development pipeline. There are several challenges to the current drug development pipeline for nervous system disorders. The fundamental etiology and pathophysiology of many nervous system disorders are unknown and the brain is inaccessible to study, making it difficult to develop accurate models. Patient heterogeneity is high, disease pathology can occur years to decades before becoming clinically apparent, and diagnostic and treatment biomarkers are lacking. In addition, the lack of validated targets, limitations related to the predictive validity of animal models - the extent to which the model predicts clinical efficacy - and regulatory barriers can also impede translation and drug development for nervous system disorders. Improving and Accelerating Therapeutic Development for Nervous System Disorders identifies avenues for moving directly from cellular models to human trials, minimizing the need for animal models to test efficacy, and discusses the potential benefits and risks of such an approach. This report is a timely discussion of opportunities to improve early drug development with a focus toward preclinical trials.

Neurosurgical Management of Psychiatric Disorders, Part B, Volume 267 in the Progress in Brain Research serial highlights new advances in the field with this new volume presenting interesting chapters on topics such as the Neurosurgical Management of Tourette Syndrome, Stereotactic Surgeries for Opioid Addiction: Patient Selection and Results, Psychiatric Disorders as Indication for Surgical Management of Drug-Resistant Temporal Epilepsy, Surgery of Autism: Is it Possible?, Psychogenic Pain: Diagnosis and Management, Stereotactic Cingulotomy and Capsulotomy for Obsessive-Compulsive Disorders: Indications and Comparative Results, and much more. Provides the authority and expertise of leading contributors from an international board of authors Presents the latest release in the Progress in Brain Research serial Updated release includes the latest information on the Neurosurgical Management of Psychiatric Disorders

Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.